Presentation of Latest Confirmatory EVX-01 Clinical Data with Key Opinion Leader Adnan Khattak

In this presentation, Professor Adnan Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion’s personalized cancer vaccines is trying to meet. After summarizing the results reported in the EVX-01 Phase 1 clinical trial, Adnan Khattak will dive into Evaxion’s latest EVX-01 Phase 2 clinical update and how these data confirm the benefits observed for this innovative AI-Immunology™ powered vaccine. In the end, a Q&A session will be held for anyone who wants to learn more about this study and its underlying technology.